EOLS
Closed
Evolus Inc
9.2
0.0 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 9.21
Day's Range: 9. - 9.625
Send
sign up or login to leave a comment!
When Written:
8.46
Evolus Inc. is a medical aesthetics company that focuses on developing and commercializing minimally invasive aesthetic products. The company was founded in 2012 and is headquartered in Newport Beach, California.
Evolus' flagship product is Jeuveau, a prescription medicine used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows. Jeuveau is similar to Botox and Dysport, but is marketed as a more affordable alternative.
In addition to Jeuveau, Evolus has a pipeline of other aesthetic products in various stages of development. The company is also focused on expanding its global presence through partnerships and collaborations with other companies.
Evolus went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol EOLS. The company has received several awards and recognitions for its innovative products and business practices.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Evolus' flagship product is Jeuveau, a prescription medicine used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows. Jeuveau is similar to Botox and Dysport, but is marketed as a more affordable alternative.
In addition to Jeuveau, Evolus has a pipeline of other aesthetic products in various stages of development. The company is also focused on expanding its global presence through partnerships and collaborations with other companies.
Evolus went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol EOLS. The company has received several awards and recognitions for its innovative products and business practices.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








